Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of CD200 protein and CD200 fusion protein in preparation of drugs for treating psoriasis

A fusion protein and psoriasis technology, applied in the field of biomedicine, can solve the problems of psoriasis pathogenesis research and unknown effect

Pending Publication Date: 2020-03-06
CHINA PHARM UNIV
View PDF8 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

CD200 / CD200R1 signaling is strongly associated with protection against autoimmune diseases, but the role of CD200 / CD200R1 signaling in the pathogenesis of psoriasis remains unknown
[0009] It has been shown at home and abroad that the use of CD200 antibody (CN10369097A), the use of CD200 mutant (CN109219614A), the use of CD200R antibody (CN101679519A), the use of CD200 in systemic lupus erythematosus (CN102698266A), the anti-CD200 antibody treatment method (CN102918062A ), CD200 and CD200R regulate bone mass through osteoclast differentiation (CN101687033), CD200 blockers and methods of use (JP2018537433) have not studied that CD200 can treat psoriasis, and CD200 may play a role in the pathogenesis of inflammatory skin diseases function (Akman- A et al., (2013) Med Sci Monit.19:888-91), but did not study the pathogenesis of psoriasis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CD200 protein and CD200 fusion protein in preparation of drugs for treating psoriasis
  • Application of CD200 protein and CD200 fusion protein in preparation of drugs for treating psoriasis
  • Application of CD200 protein and CD200 fusion protein in preparation of drugs for treating psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] CD200 protein and CD200Fc fusion protein inhibit macrophage migration

[0041] The development of macrophage psoriasis plays an important role, and CD200 protein and fusion protein can inhibit the migration of macrophages. The specific methods and results are as follows:

[0042] Methods: Firstly, peritoneal macrophages should be obtained. Mice were injected intraperitoneally with 1 ml of autoclaved 5% thioglycolate broth daily. After three consecutive days, the mice were sacrificed, the mouse ascites was sucked out with a syringe, and after washing with PBS, the cells were incubated with penicillin (100 U / ml), streptomycin (100 mg / ml) and 10% fetal bovine serum (FBS). Cultured in DMEM. After 5 hours, the suspended cells were aspirated and washed three times with cold PBS to obtain adherent cells. Adherent macrophages were digested with 0.25% trypsin. The cell suspension in DMEM medium was placed in the small chamber above the transwells (8 μm) coated with Matrigel...

Embodiment 2

[0054] Effects of CD200 protein and CD200Fc fusion protein on the release of inflammatory factors

[0055] The inflammatory factors secreted by macrophages can aggravate the inflammatory response of psoriasis, and CD200 protein and fusion protein can inhibit the release of inflammatory factors from macrophages. The specific methods and results are as follows:

[0056] Method: The peritoneum of normal mice and model group was extracted and cultured, the process is shown in Example 1. The cells were divided into three groups: normal group, CD200 protein or CD200Fc fusion protein treatment group, and model group. After 24 hours of culture, the cell supernatant was collected for ELISA detection. Kits were purchased from Tianjin Anoric Biotechnology to detect the levels of IL-1β, IL-6 and TNF-α.

[0057] Results: After treatment with CD200 protein and CD200Fc fusion protein, IL-1β(F(2,12)=12.28, P=0.0012, Newman-Keuls'test), IL-6(F(2,12)=28.21, P image 3 As shown in Table 5-8, it...

Embodiment 3

[0068] Effects of CD200 protein and CD200Fc fusion protein on the proliferation of keratinocytes by macrophages

[0069] CD200 protein and CD200 fusion protein can indirectly inhibit the excessive proliferation of keratinocytes by inhibiting the activation of macrophages. The markers of keratinocyte proliferation used in this experiment are S100A7 and S100A8. The specific methods and results are as follows:

[0070] Method: Firstly, keratinocytes need to be obtained: separate skin tissue from newborn mice and cut into pieces. The minced skin tissue was digested with 25 U / ml dispase overnight, and then digested with 0.05% trypsin-EDTA for 15 minutes. After washing with cold PBS, the suspension cells were cultured with 154CF medium. Keratinocytes were co-cultured with macrophages containing CD200 protein or CD200Fc fusion protein in the remaining medium above, CD200 protein and CD200Fc fusion protein were used as treatment groups, keratinocytes were co-cultured with untreated ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of CD200 in psoriasis, and belongs to the field of biological medicines. The invention specifically relates to an application of CD200 protein or CD200 fusion protein in treatment of psoriasis. Through the research, when an effective amount of exogenous CD200 protein or CD200 fusion protein is given in vitro, NF-kappa B signal transduction can be inhibited, the activation of inflammatory macrophages is inhibited, the secretion of IL-1beta, IL-6 and TNF-alpha inflammatory factors and the excessive proliferation of keratinocytes can be reduced, so that theprotein can be applied to psoriasis treatment.

Description

technical field [0001] The invention relates to the field of biomedicine, more specifically, to the application of CD200 protein and CD200 fusion protein in treating psoriasis. Background technique [0002] Psoriasis, also known as psoriasis, is a common chronic and easily relapsing inflammatory skin disease with characteristic skin damage. It has the characteristics of high incidence, chronicity, stubbornness, and easy relapse after healing. Great physical pain and great mental stress. Psoriasis, a common chronic autoimmune disease caused by the interaction between keratinocytes and immune cells, is associated with inflammatory skin and affects 2-3% of the population worldwide. Symptoms of psoriasis include erythema, skin hyperplasia, scaling, and keratinocyte hyperproliferation, and lesions include acanthosis due to keratinocyte hyperproliferation and lymphadenopathy and parakeratosis due to abnormal keratinocyte differentiation. [0003] Although both psoriasis and syst...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61K47/68A61P17/06
CPCA61K38/1774A61K47/6849A61P17/06Y02A50/30
Inventor 徐寒梅李东平金欣荣
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com